Involvement of microRNA181a in differentiation and cell cycle arrest induced by a plant-derived antioxidant carnosic acid and vitamin D analog doxercalciferol in human leukemia cells.

Author: DuggalJyoti, HarrisonJonathan S, StudzinskiGeorge P, WangXuening

Paper Details 
Original Abstract of the Article :
1,25-dihydroxyvitamin D3 (1,25D) has been shown to influence differentiation, cell proliferation and cell death in cultured leukemia cells. However, its clinical use is limited by its hypercalcemic effects. An analog of 1,25D, doxercalciferol (1-D2), has anti-tumor activity, with markedly reduced ca...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.2174/2211536611201010026

データ提供:米国国立医学図書館(NLM)

MicroRNA181a: A Key Regulator of Differentiation and Cell Cycle Arrest in Leukemia

Leukemia, a formidable foe in the fight against cancer, continues to demand our attention. This research, like a camel navigating a treacherous dune field, explores the role of microRNA181a in differentiation and cell cycle arrest induced by carnosic acid and doxercalciferol in leukemia cells. The study reveals that the combination of carnosic acid, a plant-derived antioxidant, and doxercalciferol, a vitamin D analog, effectively induces differentiation and cell cycle arrest in leukemia cells, potentially offering a new therapeutic strategy for combating this disease.

MicroRNA181a: A Potential Target for Leukemia Treatment

The study highlights the crucial role of microRNA181a in mediating the anti-leukemic effects of carnosic acid and doxercalciferol. The researchers demonstrated that modulation of microRNA181a levels significantly impacted the effectiveness of these agents, suggesting that this microRNA could serve as a potential target for future leukemia treatments.

Leukemia and MicroRNA181a: Exploring the Desert of Cancer Biology

This research opens a new avenue for understanding and treating leukemia. Further investigations are needed to fully elucidate the complex interactions between microRNA181a, carnosic acid, and doxercalciferol in leukemia cells. However, the study provides a promising foundation for developing novel therapies that could potentially improve the lives of patients battling this devastating disease.

Dr.Camel's Conclusion

The desert of cancer biology is vast and often unforgiving, but we are constantly uncovering new pathways for understanding and treating this disease. This research reminds us of the power of natural compounds and the intricate role of microRNAs in cellular processes. Through continued exploration and innovation, we can illuminate the path towards effective treatments and ultimately conquer the challenges of leukemia.

Date :
  1. Date Completed 2014-12-11
  2. Date Revised 2019-12-10
Further Info :

Pubmed ID

25048087

DOI: Digital Object Identifier

10.2174/2211536611201010026

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.